Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.
A 32-year-old HIV-1 positive man was diagnosed with Castleman's disease following a long history of constitutional symptoms. Primary therapy with single agent rituximab was associated with a near complete response. During this time, his KSHV (Kaposi's sarcoma-associated herpesvirus) viral load decreased and we also observed immediate, large and sustained decreases in interleukin-6 (IL-6) and tumor necrosis factor-alpha levels (TNF-alpha). This highlights the close association between circulating cytokines such as IL-6 and virally-induced malignancy.
Newsom-Davis
Tom
T
Departments of Oncology & HIV Medicine, Chelsea & Westminster Hospital, London SW10 9NH, UK.
Bower
Mark
M
Wildfire
Adrian
A
Thirlwell
Christina
C
Nelson
Mark
M
Gazzard
Brian
B
Stebbing
Justin
J
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D005871:Castleman Disease / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism*; D008297:Male; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab